Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Cingulate Inc. issued 25,786 shares of common stock to a lender for in exchange for a portion of the debt owed.
- Security
- common stock
- Shares
- 25,786 shares
- Purchaser
- a lender
- Consideration
- in exchange for a portion of the debt owed
Exact text from the filing
On February 6, 2026, Cingulate Inc. (the “ Company ”) issued 25,786 shares of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), at a value of $6.16 per share to a lender in exchange for a portion of the debt owed to such lender.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Cingulate Inc. issued units consisting of convertible preferred stock and warrants of unit to certain affiliates of Falcon Creek Capital Advisor LLC and other institutional investors for $12 million gross proceeds.
- Security
- unit
- Shares
- units consisting of convertible preferred stock and warrants
- Purchaser
- certain affiliates of Falcon Creek Capital Advisor LLC and other institutional investors
- Consideration
- $12 million gross proceeds
Exact text from the filing
Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules KANSAS CITY, Kan., February 17, 2026 — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced the successful closing of a $12 million private investment in public equity (PIPE) financing, led by certain affiliates of Falcon Creek Capital Advisor LLC (“Falcon Creek Capital”).
View on SEC.gov